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Malaysia [15], 8 weeks in Ghana [5] and 5 weeks
in Botswana [14], but longer than that in other
studies [8,16]. As reported elsewhere [9,12], the
results indicated that the institutional delay was
more signiﬁcant than delays in diagnosis and
treatment. The most common reasons for a
doctor’s delay were a low index of suspicion
for tuberculosis on the part of physicians and
healthcare system, as well as laboratory delays
and the distance to a hospital. Previous studies
have reported similar ﬁndings, and have also
identiﬁed under-utilised chest X-ray examination
facilities and a failure to perform sputum smear
examinations as important reasons for a doctor’s
delay [11,12,14,16,17].
In conclusion, delays in diagnosis and treat-
ment of pulmonary tuberculosis were a common
problem at the Heybeliada Center for Chest
Disease and Thoracic Surgery. Delayed diagnosis
results in a more advanced disease state, the
likelihood of complications, increased mortality,
and enhanced transmission of infection among
healthcare workers and in the community. Delays
should be reduced for good control of tuberculo-
sis. Education of physicians and the public about
tuberculosis, reductions in healthcare system and
laboratory delays, together with improvements in
economic status and sociocultural factors, are the
most important factors likely to reduce delays in
diagnosis and treatment among tuberculosis
patients.
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ABSTRACT
Vancomycin serum concentrations were deter-
mined for 1737 patients treated with either 2 · 1
g of vancomycin or 4 · 500 mg daily (780 pa-
tients), according to current nomograms, or by
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continuous infusion (957 patients) with a loading
dose (1 g) and a total of 2–6 g daily. Trough serum
concentrations were determined after 36–48 h.
Adequate serum levels for the treatment of a
normal methicillin-resistant Staphylococcus aureus
(MRSA) and a glycopeptide-intermediate S. aure-
us (GISA) were observed in 81% and 20.9% of
patients, respectively. The data support theoretical
arguments that higher and more sustained serum
levels of vancomycin, obtained by continuous
infusion, may enhance clinical efﬁcacy.
Keywords Continuous infusion, GISA, MRSA, serum
concentration, vancomycin
Original Submission: 19 May 2005; Revised Submis-
sion: 13 June 2005; Accepted: 9 July 2005
Clin Microbiol Infect 2005; 12: 92–95
10.1111/j.1469-0691.2005.01306.x
More than 45 years after the introduction of
vancomycin for the treatment of severe antibi-
otic-resistant staphylococcal infections, there are
still controversies regarding the determination
and interpretation of vancomycin serum concen-
trations [1–7]. Older studies focused on toxicity
without considering clinical efﬁcacy [8–11]. When
performed and reported, serum assays always
involved very few patients and the interpretation
of the results was debatable. The aims of the
present study were to determine the trough
vancomycin serum concentrations in a large
number of patients, and to consider the rationale
for modifying the currently recommended
‘acceptable therapeutic range’, taking into account
the pharmacokinetics, toxicity and antibacterial
activity of vancomycin in combination with the
clinical results.
Serum assays are performed routinely in the
Hospital Saint Joseph, Paris, for all patients
receiving vancomycin therapy. In total, 1737
patients treated during 1998–2004 were enrolled
in the study. The patients received either 1 g of
vancomycin every 12 h, or 500 mg every 6 h
(according to current nomograms), or were trea-
ted by continuous infusion with a loading dose
(1 g) and a total daily dose of 2–6 g. The daily
dose was then adapted after further monitoring.
The ﬁrst trough serum assays were performed at
steady state after treatment for 36–48 h; 5–10 mL
of blood was drawn from the controlateral vein,
and assays were performed within 1 h by the
ﬂuorescence polarisation immunoassay (TDx;
Abbott Diagnostics, Rungis, France). The results
are presented in Table 1.
When the ‘Mississippi mud’ was released
during the 1950s, it contained impurities respon-
sible for renal and ototoxicity or allergic reactions
[8–11]. Cases of toxicity occurred during the ﬁrst
10 years of vancomycin use, often in patients
receiving other nephrotoxic compounds, or who
had pre-existing renal dysfunctions. In the pre-
sent study, <1% of the 1737 patients treated
during the 7-year period of the study with trough
concentrations £40 mg ⁄L suffered from vancomy-
cin-related toxicity (N. Desplaces and A. Ben Ali,
personal communications). Vancomycin has a
narrow spectrum of activity, restricted to most
Gram-positive bacteria, and is the drug of choice
for the treatment of methicillin-resistant Staphylo-
coccus aureus (MRSA). The vancomycin MIC for
MRSA is 1–2 mg ⁄L for fully vancomycin-suscept-
ible strains. All strains with MICs ‡ 4 mg ⁄L can
be considered to be (hetero) glycopeptide-inter-
mediate S. aureus (GISA) on the basis of popula-
tion analysis proﬁles [12,13].
Vancomycin inhibits peptidoglycan synthesis
by binding to the D-Ala-D-Ala terminus of the
nascent murein monomer, resulting in the inhibi-
tion of cell-wall synthesis. Only 50% of the
vancomycin arriving at the surface of a staphylo-
coccus will reach the target site. GISA are char-
acterised by a thicker cell-wall with increased
amounts of peptidoglycan, and the increased
quantities of unprocessed D-Ala-D-Ala cause
Table 1. Trough vancomycin serum levels (ﬁrst assay
only) obtained in 1737 patients after either 2–4 separate
doses (n = 780) or administration by continuous infusion
(n = 957)
Serum level
(mg ⁄L)
No. patients with the indicated serum levela
2–4 separate doses Continuous infusion
<5 148 (19.0%) 15
5–10 204 60 (7.9%)
10–15 160 212
15–20 103 173
20–25 70 (68.8%) 176
25–30 35 121 (71.2%)
30–35 22 74
35–40 12 59
>40 26 (12.2%) 67 (20.9%)
aDialysed patients excluded.
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increased ‘trapping’ and ‘clogging’, resulting in
higher vancomycin MICs and the increased ino-
culum effect observed with GISA in comparison
with fully vancomycin-susceptible strains [12–15].
This can explain the therapeutic failures observed
in the treatment of GISA infections, where a
concentration of 8–16 mg ⁄L is required at the site
of infection in order to totally inhibit large
numbers of bacteria (108 CFU ⁄ g), in contrast to
3–4 mg ⁄L for a fully vancomycin-susceptible
strain [12–14]. Continuous infusion increases dif-
fusion of vancomycin in body ﬂuids and tissues,
with the result that a more sustained concentra-
tion is achieved more quickly.
The ‘therapeutic range’ for vancomycin was
established in the early 1980s in four healthy
subjects who each received 500 mg of vancomycin,
yielding peak concentrations of 20–40 mg ⁄L and
trough concentrations of 5–10 mg ⁄L, obviously
without any clinical correlation [13]. Vancomycin
is 50%protein-bound in serum,which explains the
2–4-foldMIC increase in vivo and the occurrence of
breakthrough positive blood-cultures, particularly
in patients infected with GISA strains [12–15]. The
tissue concentration of vancomycin does not
exceed 30–40% of the serum concentration [13].
Other important factors to be considered include
the decreased in-vivo bactericidal activity, the
inoculum effect, the attachment of staphylococci
to foreign bodies, and the production of bioﬁlm. A
trough vancomycin serum level of 15–25 mg ⁄L is
mandatory for the treatment of a fully glycopep-
tide-susceptible MRSA, with 30–40 mg ⁄L (admin-
istered by continuous infusion) being required for
treatment of a GISA infection [12,16]. In the present
study of 1737 patients who were treated either
conventionally or with continuous infusion, 19%
and 7.9%, respectively, of those infected with a
fully vancomycin-susceptible S. aureus, and 87.8%
and 79.1%, respectively, of those infected with a
GISA isolate failed to receive an adequate dose.
Similarly, a study of paediatric patients reported
that <20% had adequate therapeutic serum levels
[6]. Theoretical aspects, often unfounded and
misinterpreted, such as nomograms based solely
on creatinine clearance, are likely to be inaccurate
for some patients [7]. Other practical considera-
tions, including cost, should not counterbalance
the risk to the patient and the consequences of
inadequate treatment [1].
Several previous reports have claimed that
clinical cure does not always correlate with vanco-
mycin serum concentrations [2,3], and no clinical
cure attributed to vancomycin can be expected if
the serum concentration remains below the MIC,
particularly in the case of GISA. Sabath [14]
reported that up to 6 g vancomycin ⁄day were
required to eliminate strains that, from the increase
inMICs observedwith a heavy inoculum (from2 to
32–64 mg ⁄L), were probably GISA. Nomograms
are necessary, but monitoring is essential for dose
adjustment and follow-up. The data presented
above strengthen the theoretical arguments that
higher and more sustained serum levels, obtained
by continuous infusion, may contribute to a better
clinical efﬁcacy.
Some investigators have suggested that deter-
mination of vancomycin serum concentrations is
unnecessary until the relationship between serum
concentration and clinical outcome has been
demonstrated [2]. However, after waiting for such
results for more than 30 years, it seems appropri-
ate to continue monitoring vancomycin serum
levels in order to ensure effective therapeutic
concentrations until the results of well-designed
clinical studies become available.
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